<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00126958</url>
  </required_header>
  <id_info>
    <org_study_id>*ZON-MW 945-02-046*</org_study_id>
    <nct_id>NCT00126958</nct_id>
  </id_info>
  <brief_title>Cost-Effectiveness in Bladder Cancer</brief_title>
  <official_title>Cost-Effectiveness of Follow-up of Patients With Superficial Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Reinier de Graaf Groep</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sint Franciscus Gasthuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vlietland Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medisch Centrum Rijnmond-Zuid, Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Havenziekenhuis, Roterdam, Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Albert Schweitzer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ikazia Hospital, Rotterdam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <brief_summary>
    <textblock>
      This randomized clinical multicentre trial aims to evaluate the efficacy of microsatellite
      analysis on voided urine to detect tumour recurrences in the follow-up of patients with
      superficial urothelialcell carcinoma (UCC). Further, this study aims to identify subgroups of
      patients with a low risk of tumour recurrence using clinico-pathologic tumour characteristics
      in combination with a genetic marker (FGFR3 gene), such that the frequency of follow-up
      contact can be reduced. The overall objective is to reduce the frequency of cystoscopy during
      follow-up in patients with superficial UCC, leading to an improvement in quality of life at
      equal or lower costs. This study evaluates the cost-effectiveness of follow-up in bladder
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The randomized clinical study consists of two intervention arms. The control arm consists of
      a conventional follow-up based on regular monitoring for urinary bladder UCC recurrences by
      cystoscopy. In the test arm a proportion of the cystoscopies is replaced by microsatellite
      analysis on voided urine. Both arms will be stratified for clinical and pathological tumour
      parameters as well as for the mutation status of the prognostic FGFR3 gene mutation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2002</start_date>
  <completion_date>July 2005</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment>500</enrollment>
  <condition>Bladder Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>urinary analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with resectable pT1 or pTa, grade G1-G2 transitional cell carcinoma of
             the bladder which is biopsy proven

        Exclusion Criteria:

          -  Patients who present or presented with a transitional cell carcinoma of the bladder,
             stage pT2 or more invasive, or carcinoma in situ (CIS) and/or G3 diagnosed in history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Th. van der Kwast, Prof PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC, JNI</affiliation>
  </overall_official>
  <overall_official>
    <last_name>E.C. Zwarthoff, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC, JNI</affiliation>
  </overall_official>
  <verification_date>August 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2005</study_first_submitted>
  <study_first_submitted_qc>August 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2005</study_first_posted>
  <last_update_submitted>February 18, 2009</last_update_submitted>
  <last_update_submitted_qc>February 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2009</last_update_posted>
  <keyword>superficial urothelial cell carcinoma</keyword>
  <keyword>urinary analysis</keyword>
  <keyword>Loss of heterozygosity</keyword>
  <keyword>FGFR3 mutation</keyword>
  <keyword>follow-up</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

